サイアザイド剤治療下にある本態性高血圧症の脂質代謝に対するパンテチンの効果

J-STAGE
  • 家入 蒼生夫
    Department of Endocrinology, Internal Medicine, Dokkyo University School of Medicine
  • 伴場 信之
    Department of Endocrinology, Internal Medicine, Dokkyo University School of Medicine
  • 黒田 久元
    Department of Endocrinology, Internal Medicine, Dokkyo University School of Medicine
  • 下田 新一
    Department of Endocrinology, Internal Medicine, Dokkyo University School of Medicine

書誌事項

タイトル別名
  • Effects of Pantethine on the Serum Levels of High-density Lipoprotein in Essential Hypertensives

抄録

Recent studies suggest that long term therapy of hypertension with thiazide may result in a decrease of serum levels of HDL-cholesterol. The present paper describes the effects of cross-over administration of trichlormethiazide alone (A) and the combination of trichlormethiazide and pantethine (B) on the serum levels of total cholesterol (TC), HDL-cholesterol (HDL), triglyceride (TG), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in essential hypertensives. Pantethine, which is one of the components of Co-enzyme A and acyl carrier protein, has been known to improve the serum levels of some lipid fractions such as HDL, TG, or TC in hypertensives and hyperlipidemic patients.<br>A or B was administered for 4 months. Each lipid fraction was determined under hunger condition at early in the morning before and after A or B. TC was not altered significantly in this study. HDL was decreased by A and increased by B, thus atherogenic index (A.I., (TC-HDL)/HDL) was increased by A, and decreased by B. Mann-Whitney analysis of the changes of HDL (ΔHDL) and A. I. (ΔA.I.) revealed that these changes were statistically significant at the level of p<0.05. The other lipid fractions were not significantly changed in this study.<br>These results suggest that to combine pantethine with trichlormethiazide in the therapy of essential hypertention maintains the HDL levels higher.

収録刊行物

  • 動脈硬化

    動脈硬化 12 (2), 349-352, 1984

    Japan Atherosclerosis Society

詳細情報 詳細情報について

問題の指摘

ページトップへ